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There are currently seven published physiologically based pharmacokinetic (PBPK) models describing
aspects of the pharmacokinetics of octamethylcyclotetrasiloxane (D4) and decamethylcyclopentasiloxane
(D5) for various exposure routes in rat and human. Each model addressed the biological and physico-
chemical properties of D4 and D5 (highly lipophilic coupled with low blood: air partition coefﬁcient
and high liver clearance) that result in unique kinetic behaviors as well differences between D4 and D5.
However, the proliferation of these models resulted in challenges for various risk assessment applica-
tions when needing to determine the optimum model for estimating dose metrics. To enhance the utility
of these PBPK models for risk assessment, we integrated the suite of structures into one coherent model
capable of simulating the entire set of existing data equally well as older more limited scope models. In
this paper, we describe the steps required to develop this integrated model, the choice of physiological,
partitioning and biochemical parameters for the model, and the concordance of the model behavior
across key data sets. This integrated model is sufﬁciently robust to derive relevant dose metrics following
individual or combined dermal and inhalation exposures of workers, consumer or the general population
to D4 and D5 for route-to-route, interspecies and high to low dose extrapolations for risk assessment.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cyclic volatile methyl siloxanes (cVMSs), such as octame-
thylcyclotetrasiloxane (D4) and decamethylcyclopentasiloxane
(D5), are lowmolecular weight silicones used in themanufacture of
high molecular weight silicone polymers and in cosmetics and
personal care products, leading primarily to low level inhalation
and dermal exposures to both workers and consumers. The hazard
proﬁle of these cVMSs have been extensively evaluated (Dekant
and Klaunig, 2015; in this issue; REACH, 2011a, b). To understandT.S. McMullin), jcampbell@
r.org (H.J. Clewell), kathy.
mandersen@thehamner.org
ironment, 4300 Cherry Creek
Inc. This is an open access article uthe inﬂuence of kinetic factors on delivered dose of these cVMSs,
our teams have conducted a comprehensive set of kinetic studies
over the last several years (Tables Se1). In association with these
time course data sets, we also developed several PBPK models
describing the biological and physicalechemical processes regu-
lating the kinetic disposition of either D4 or D5 in various species
after different routes of exposure (Andersen et al., 2001; Reddy
et al., 2003; Sarangapani et al., 2003; Reddy et al., 2007, 2008)
(Tables Se2). Kinetic data and associated models were also derived
to evaluate the disposition of D4 following implantation (Thrall
et al., 2008) but were not used for our model development. The
individual models focused on speciﬁc data sets in order to describe
the kinetic behavior of either D4 or D5 in rats or humans following
various routes of administration.
The ﬁrst modeling work for cVMSs with D4 (Andersen et al.,
2001) utilized data from a series of inhalation kinetic studies in
the rat (Plotzke et al., 2000). This initial PBPK analysis uncovered a
suite of processes that regulate siloxane kinetics in the rodent thatnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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organic compounds. Among those characteristics were low blood:
air partitioning, high fat: blood partitioning, high metabolic clear-
ance by the liver, and slower loss of D4 from tissues than expected
for simple well-mixed, ﬂow-limited uptake compartments. In
addition, a discrepancy between the rate of D4 elimination via
exhalation and the associated blood levels following inhalation
exposure indicated the presence of a pool of D4 in the plasma that
was not available for exhalation. These observations led to inclusion
of several ‘deep-tissue compartments’ to account for slow, multi-
phasic loss after cessation of exposure, a pool (compartment) in
blood assumed to represent lipoproteins, called a mobile lipid pool
(MLP), and multiple fat compartments to describe the longer-time
exhalation curves indicative of slower release of D4 from fat com-
partments. Sarangapani et al. (2003) expanded the Andersen et al.
(2001) model to include a kinetic description of D4 following oral
and dermal exposure.
D5 has even greater lipophilicity and lower blood: air parti-
tioning than D4. Successful curve ﬁtting with D5 time course data
(Tobin et al., 2008) required addition of other deep tissue com-
partments, including a deep tissue store within the blood itself
(Reddy et al., 2008). Thus, the rat D5 inhalation description had the
largest number of tissue compartments of all the cVMSs PBPK
models. The in vitro dermal absorption and in vivo dermal exposure
studies in rats (Jovanovic et al., 2008) and the human volunteer
inhalation studies (Utell et al., 1998) lacked the detailed tissue time
courses required for establishing the presence and characteristics
of deep tissue compartments. However, the dermal studies did
provide information to characterize the dynamics of uptake at the
skin surface while the human inhalation studies provided time-
course information for metabolites to determine the pathways
and time course of elimination of various low molecular weight
metabolites (Utell et al., 1998). Overall the human modeling efforts
for D4 and D5 adequately simulated the time-course biomarker
data of D4 and D5 collected during inhalation or dermal exposure
(Reddy et al., 2007).
Although each of the contributions on PBPK modeling with D4
and D5 produced good correspondence betweenmodel predictions
and available data sets, the compartmental structures of these
models varied according to speciﬁc data sets and the goals of model
development. Unquestionably, the existence of multiple models
enhances the ability to capture behaviors in the individual studies.
Conversely, their proliferation presents some challenges for various
risk assessment applications where it becomes difﬁcult to deter-
mine the optimum model for estimating speciﬁc dose metrics. To
improve the use of these PBPK models for risk assessment, we built
a single integrated multi-compound, and multi-dose (MC-MD)
route PBPK model for cVMSs that preserved the key chemical-
speciﬁc biological and kinetic features determined in previous
PBPK models. This contribution describes the steps required to
develop this uniﬁed model, the choice of physiological, partitioning
and biochemical parameters for the model, and the concordance of
the model behavior across key data sets.
2. Methods
We used a three step process to construct a multi-compound,
multi-dose route model for cVMSs that included 1) combining
inhalation rodent model structures across compounds 2) coordi-
nating model across species 3) combining routes of exposure.
Table 1 shows the key model features incorporated into the current
model compared to those used previously. The current computer
code uses a nested algorithm to toggle speciﬁc tissues on or off
depending on the chemical, the animal species and exposure route.
The mass balance equations that describe the rate of change of D4and D5 and their metabolites in various tissues are in the supple-
mental material (S-4). Computer code, speciﬁc scripts that repro-
duce all ﬁgures in this manuscript and associated documentation
can be obtained from the corresponding author (TSM). The series of
differential equations were solved by numerical integration using
the Gear Algorithm for stiff systems in acslX version 11.8.4 (AEgis,
Technologies Group, Inc, Huntsville, Alabama, USA).
2.1. Step 1: Combining the inhalation rodent model structures
across compounds (D4 and D5)
As a ﬁrst step, we developed a single compartmental suite for D4
and D5 based on inhalation exposures (Fig. 1aed) using the struc-
ture from the rat D5 inhalation model (Reddy et al., 2008) and
modiﬁed parameters and compartments for D4 based on earlier
work. With D5, we retained all model features from Reddy et al.
(2008) with the exception of metabolism. D4 exhibited saturable
hepatic metabolism around the highest concentration (700 ppm)
(Sarangapani et al., 2003). At the highest exposure concentration
(160 ppm) of D5, blood concentrations were approximately 10-fold
lower than D4 concentrations (Reddy et al., 2008), indicative of
ﬁrst-order metabolism. For the purposes of developing a common
model structure across compounds, we included saturable meta-
bolism into the D5 structure. This integrated PBPK model has six
tissue compartments including blood, fat, lung, liver, slowly
perfused tissues, and rapidly perfused tissues.
Physiological parameters (Table 2) such as ventilation rate [L/hr]
and tissue blood ﬂow rates (as percentage of cardiac output, L/hr)
were from Brown et al. (1997). The scaling function used for the
metabolism parameters and the ventilation rate was changed from
BW0.7 to BW0.75 to provide consistent scaling throughout the
model. Starting values for the chemical speciﬁc model parameters
were adopted from the previous published models and re-
parameterized, if necessary, by comparing the model simulations
with experimental data. All model parameters were separately
estimated for male and female with the exception of the partition
coefﬁcients. The data sets and decisions made in developing the
integrated model are outlined below.
2.1.1. Datasets
For both D4 and D5 kinetic studies (Plotzke et al., 2000a; Tobin
et al., 2008), parent test material was synthesizedwith a theoretical
maximum of one 14C radio-labeled carbon attached to each silicon
atom. After exposure and tissue collection, concentrations of parent
test material were measured in blood and select tissues and total
radioactivity was determined in blood and the same tissues. In
addition, radioactivity wasmeasured in urine, feces, expired air and
“remaining carcass.” The concentration of total metabolites was the
difference between total radioactivity and the parent material
concentrations.
D4: The tissue time-course data for total radioactivity and
parent chemical from 14C-D4 inhalation studies in male and female
rats were collected following a single 6-h exposure 7, 70, or
700 ppm or multiple exposures for 6 h/day for 15 days to 7 or
700 ppm of D4 (Plotzke et al., 2000a). Exhaled breath, blood, liver,
fat, lung, urine, and feces were used to construct the model. The
PBPK model structure had two different fat compartments. In our
current model structure, simulations for the concentration in the
“distributed” fat were compared to the fat tissue data rather than
the “diffuse fat” as was done previously.
D5: The tissue time-course data for total radioactivity and
parent chemical from 14C-D5 inhalation studies in male and female
rats were collected following a single 6-h exposure to 7 or 160 ppm
or following multiple exposures (160 ppm) for 6 h/day for 15 days.
The data used for determining model parameters included exhaled
Table 1
Comparison of the key model features in the rat reference models and the current multi-purpose rodent PBPK model.
Model
compartment
Reference D4 model (Saragapani et al., 2003) Reference D5 model (Reddy et al., 2008) Multi-purpose
PBPK model
Blood Deep compartment in venous blood Deep compartment in both venous and arterial blood
compartments
Adapted D5
model feature
Mobile lipid
pool (MLP)
A storage depot that transports D4 from liver to diffused fat
compartment in venous blood compartment
Detailed description of MLP movement from liver (via venous
blood) to distributed fat (via arterial blood)
Adapted D5
model feature
Fat Consisted of diffused and distributed fat compartments with extremely
low blood ﬂow rate to fat (<0.1% of QC)
Consisted of diffused and distributed fat compartments with
literature-based blood ﬂow rate to fat (6%)
Adapted D5
model feature
Liver Saturable and inducible metabolism pathway 1st order metabolism pathway Adapted D4
model feature
Skin Within the body (blood ﬂow accessible) Only considered as the top layer (a depot outside the body) Adapted D5
model feature
Fig. 1. Diagram of the multi-purpose D4 and D5 PBPK model structure that describes (a) the time ecourse tissue concentrations of D4 and D5 (b) hydroxylated D5 metabolite sub-
model (c) short chain silanol metabolite sub-model (d) production and distribution of the mobile lipid pool (e) dermal uptake of D4 and D5 in humans.
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et al., 2008).2.1.2. Model structure and parameter estimation
Physiological values used in the model are listed in Table 2.
Model parameter values for D4 and D5 are listed in Tables 3 and 4.
Blood: The blood compartment description from Reddy et al.
(2008) was retained. The plasma compartment was converted toa blood compartment containing both arterial and venous blood.
Each of these compartments has a deep compartment (see deep
tissue compartment description below).
Liver and Mobile Lipid Pool: A ‘mobile lipid pool’ (MLP)
compartment describes the transport of a bound form of D4 and D5
that is formed in the liver, transported from the liver to the venous
blood as “venous blood MLP” and then enters the arterial blood as
“arterial blood MLP” via ﬂow-limited transport. The arterial blood
Table 2
Physiological parameters for cyclic siloxane multi- purpose PBPK model.
Physiological parametera Rat Human
Tissue volumes (fraction of BW)
Body weight (kg) BW (kg) 0.185 70
Blood VBLDc 0.074 0.079
Diffuse fat VFATDIFFc 0.063 0.214
Distributed fatc VFATDISTc 0.007 0.000
Liver VLIVc 0.034 0.026
Lung VLNGc 0.005 0.008
Rapidly perfused VRAPc 0.100 0.080
Slowly perfused VSLWc 0.627 0.437
Blood Flows (fraction of QCC)
Cardiac output QCc [L/hr/kg0.75] 15 Variesb
Alveolar ventilation QPc [L/hr/kg0.75] 15 Variesd
Diffuse fat QFATDIFFc 0.063 0.052
Distributed fatc QFATDISTc 0.007 0.000
Liver QLIVc 0.183 0.227
Rapidly perfused QRAPc 0.411 0.472
Slowly perfused QSLWc 0.336 0.249
a All physiological parameter values obtained from Brown et al. (1997).
b (6.85* log10(Age) þ 16.8)* 60.0.
c Distributed fat turned off for humans.
d Study speciﬁc based on measured values (Utell et al., 1998).
Table 3
D4 speciﬁc parameters for Cyclic Siloxane Multi-Purpose PBPK Model.
D4 speciﬁc parametersa
Parameter Rat Human
Partition Coefﬁcients (unitless)
Blood:air PBld 0.85 0.96
Diffuse fat:air PFatDiffAir 600 600
Distributed fat:air PFatDistAir 100 NA
Liver:air PLivAir 21.2 21.2
Lung:air PLngAir 7.84 7.84
Rapidly perfused:air PRapAir 8.47 8.47
Slowly perfuse:air PSlwAir 8.47 8.47
Diffusion Coefﬁcients (unitless) Male Female Male Female
Diffuse fat PermFatDiff 0.4 0.5 1 1
Distributed fat PermFatDist 0.3 0.3 NA NA
Slowly perfused PermSlw 1 1 0.045 0.045
Metabolic Parameters
Maximal capacity Vmax[mg/hr/BW0.75] 3.08 3.08 62 62
Afﬁnity constant Km [mg/L] 0.5 0.5 10 10
Mobile Lipid Pool (MLP) Parameters [/hr]
Production rate of MLP KMLP 0.0408 0.03 3.78 3.78
Clearance from MLP compartment Kremoval 0.055 0.1 0.39 0.39
Mass Transfer Parameters for Deep Compartments [/hr]
Into deep arterial blood kArtBldDeepIn NA NA NA NA
Out of deep arterial blood kArtBldDeepOut NA NA NA NA
Into deep venous blood kVenBldDeepIn NA NA NA NA
Out of deep venous blood kVenBldDeepOut NA NA NA NA
Into 1st deep lung compartment kLngDeep1In 0.018 0.0075 5.0 5.0
Into 2nd deep lung compartment kLngDeep2In NA NA 0.001 0.001
Out of 1st deep lung compartment kLngDeep1Out 0.0166 0.02 NA NA
Out of 2nd deep lung compartment kLngDeep2Out NA NA NA NA
Into 1st deep liver compartment kLivDeep1In 0.0006 0.0006 0.55 0.55
Into 2nd deep liver compartment kLivDeep2In NA NA NA NA
Out of 1st deep liver compartment kLivDeep1Out 0.009 0.009 0.13 0.13
Out of 2nd deep liver compartment kLivDeep2Out NA NA NA NA
Into deep fat compartment kFatDeepIn NA NA 0.23 0.23
Out of deep fat compartment kFatDeepOut NA NA 0.11 0.11
Dermal Absorption Rate Constants
Evaporation from skin surface kEvapC [mg/hr-cm2] NA NA 9.0 9.0
Evaporation from skin tissue kSknOutC [/hr] NA NA 380.0 380.0
Absorption rate from skin surface to skin tissue kSknIn [mg/hr-cm2] NA NA 200.0 320.0
Absorption rate from skin to blood kSknBld [/hr] NA NA 0.045 0.045
a Source of parameter (experimental or model derived) and parameterization process for each parameter is discussed in detail in the text.
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of D4 and D5 is distinct from the free circulating concentrations of
D4 and D5; it is unavailable for exhalation, metabolism andequilibration with tissues. The “MLP” likely represents cVMS
associated with circulating lipids, such as lipoproteins and trans-
ported in the body with these lipids (Looney et al., 2000; Andersen
Table 4
D5 speciﬁc parameters for Cyclic Siloxane Multi-Purpose PBPK model.
D5 speciﬁc parametersa
Parameter Rat Human
Partition Coefﬁcients (unitless)
Blood:air PBLD 0.55 0.5
Diffuse fat:air PFATDIFFAIR 1436 1436
Distributed fat:air PFATDISTAIR 1436 1
Liver:air PLIVAIR 11.1 11.1
Lung:air PLNGAIR 45.36 45.36
Rapidly perfused:air PRAPAIR 3.4 3.4
Slowly perfuse:air PSLWAIR 7 7
Diffusion Coefﬁcients (unitless) Male Female Male Female
Diffuse fat PERMFATDIFF 0.026 0.027 1 1
Distributed fat PERMFATDIST 0.02 0.03 NA NA
Slowly perfused PERMSLW 0.05 0.06 1 1
Metabolic Parameters
Maximal capacity Vmax [mg/hr/BW0.75] 30 20 11 10
Afﬁnity constant Km [mg/L] 20 20 10 10
Mobile Lipid Pool (MLP) Parameters [/hr]
Production rate of MLP KMLP 4 3 3.0 2.0
Clearance from MLP compartment Kremoval 2.0 1.7 1.0 0.5
Mass Transfer Parameters for Deep Compartments [/hr]
Into deep arterial blood kArtBldDeepIn 0.0016 0.0026 NA NA
Out of deep arterial blood kArtBldDeepOut 0.006 0.003 NA NA
Into deep venous blood kVenBldDeepIn 0.0016 0.0026 NA NA
Out of deep venous blood kVenBldDeepOut 0.006 0.003 NA NA
Into 1st deep lung compartment kLngDeep1In 0.6 0.05 3 4
Into 2nd deep lung compartment kLngDeep2In 0.001 0.001 NA NA
Out of 1st deep lung compartment kLngDeep1Out 0.6 0.6 1 0.0708
Out of 2nd deep lung compartment kLngDeep2Out 0.007 0.007 NA NA
Into 1st deep liver compartment kLivDeep1In 0.15 0.5 2.17 0.438
Into 2nd deep liver compartment kLivDeep2In 0.004 0.003 NA NA
Out of 1st deep liver compartment kLivDeep1Out 0.2 0.5 0.0508 0.195
Out of 2nd deep liver compartment kLivDeep2Out 0.003 0.006 NA NA
Into deep fat compartment kFatDeepIn NA NA NA NA
Out of deep fat compartment kFatDeepOut NA NA NA NA
Dermal Absorption Rate Constants
Evaporation from skin surface kEvapC [mg/hr-cm2] NA NA 4.26 4.26
Evaporation from skin tissue kSknOutC [/hr] NA NA 0.43 0.498
Absorption rate from skin surface to skin tissue kSknInC [mg/hr-cm2] NA NA 105.09 180.0
Absorption rate from skin to blood kSknBld [/hr] NA NA 0.0009 0.00065
a Source of parameter (experimental or model derived) and parameterization process for each of parameter is discussed in detail in the text.
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The time-course concentrations of the parent chemical and the
metabolites in the liver, blood, and urine were used to estimate the
MLP parameters. The initial production and clearance rate con-
stants of the MLPs were from Sarangapani et al. (2003) and Reddy
et al. (2008) and these parameters were converted into the
appropriate units for this current model. The MLP clearance rate
([1/hr]) in our model (Kremoval) was calculated from CLmlp (clear-
ance rate [L/hr]) used in the Reddy et al. (2008) D5 rat inhalation
model as follows:
Kremoval ¼ ðQFat*ClMLPÞ=ðQFatþ ClMLPÞ=VArtBld
MLP parameter values for this model were then manually
optimized to ﬁt the single-exposure experimental data.
Fat: The description of various fat tissues was also from Reddy
et al. (2008). There are two compartments representing separate
types of fat: distributed and diffuse fat. The distributed fat repre-
sents depots, such as perirenal or abdominal fat that are readily
identiﬁable in the body. The diffuse fat compartment represents
depots that are more widely distributed in multiple tissues
throughout the body. Initial values for fat tissue parameters were
taken from the original models and optimized by visual compari-
sons of the simulated D4 or D5 concentration in the distributed fat
compartment to the measured fat concentration.
Deep Tissue Compartments: The previously developed rat modelshad “deep compartments” to describe the time-course kinetic
behavior of the cVMSs in the lung, liver, fat and blood compart-
ments over longer periods of exposure and observation. These deep
tissue compartments represent storage depots fromwhich the free
parent chemical is released ﬁrst to the tissues themselves and then
to systemic circulation (Reddy et al., 2008). They were included
because the more conventional one-compartment descriptions of
these tissues did not adequately reﬂect tissue time course after
exposures. D4 and D5 move between the tissue compartments and
deep compartments by diffusional transport. Due to its higher
lipophilicity, ﬁtting the tissue data time courses for D5 required two
sequential deep compartments in the lung and liver. In the inte-
grated model these additional deep compartments toggle off when
simulating D4 kinetics. This diffusion descriptionwas changed from
a concentration based compartment used in the Reddy et al. (2008)
model to a mass based compartment to avoid the need to include
an estimate of the volume of tissue deep compartments. The
parameter values from the Reddy et al. (2008) model were kept
constant in our model. Reddy et al. (2008) provides a detailed
description of the parameterization process used to obtain the deep
tissue compartment rate constants.
Metabolism: Hepatic metabolism of D4 and D5 occurs by methyl
group-oxidation, rearrangement of the subsequent Si eCH2OH to
SiOCH3 followed by hydrolysis with ring opening to produce a se-
ries of linear silanols that are excreted into the urine. Inducible
metabolism of D4 saturates at higher doses in the male rat and
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metabolism of D5 was linear at the exposure levels evaluated in the
kinetic rodent studies. This current multi-compound model in-
corporates saturable MeM kinetics for both D4 and D5; however,
based on the Km values for binding, D5 metabolism is always in a
linear range even in the rat.
The time-course concentrations of the parent chemical and the
metabolites in the liver, blood, and urine were used to estimate
metabolic constants for this model. Thework on D4 by Sarangapani
et al. (2003) and D5 by Reddy et al. (2008) provided initial values
for these parameters. Reddy et al. (2008) described D5 metabolism
with a ﬁrst order rate constant, kmet where kmet ¼ Vmax/Km. We
used a sequential parameterization process to determine the
maximum metabolic rate constant (Vmax) and the Michae-
liseMenten constant (Km) from the ﬁrst-order rate constant. We
ran the Reddy D5 model at 160 ppm (the highest exposure con-
centration) to obtain the peak concentration of free D5 in venous
blood leaving the liver, a concentration approaching maximal ve-
locity of the enzyme (Vmax). We then set Km to a value approxi-
mately 50 times higher than the simulated CVliv from 160 ppm
exposure to estimate Vmax. After ﬁtting to estimate Vmax, Km was
estimated using the equation Vmax/Km ¼ kmet. Final metabolism
parameters were then adjusted to provide a good visual repre-
sentation of the time course data for tissues and metabolites.
Metabolites: A compartmental model with two ﬁrst-order
clearance rates was used to describe the distribution and urinary
elimination of a bulk pool of short chain silanol metabolites
(Fig. 1c). Final model parameters were determined by visual opti-
mization using the blood time-course data for the total metabolites
following a single 6-h inhalation exposure to 160 ppm D5 or 7, 70
and 700 ppm D4.
D5 metabolism produces a lipophilic cyclic metabolite, pre-
sumably hydroxyl-D5, which has a methyl group replaced by a
hydroxymethyl or methoxy group. A ﬁve-compartment metabolite
model adapted from the D5 rat inhalation model was included in
our integrated model to simulate concentrations of this metabolite
in plasma, selected tissues and urine (Fig. 1b). In the sub-model for
the metabolite, the cyclic D5 metabolite undergoes further meta-
bolism to produce linear silanols of variable chain length similar to
D4.
Partition coefﬁcients: Various approaches were used previously
to derive tissue/blood partition coefﬁcients (PCs) for D4 and D5. For
the combined model, the partition coefﬁcients for D4 were mainly
adapted from Sarangapani et al., 2003. Initial estimates of the tis-
sue: blood PC's were ﬁrst derived based on in vitro measurements
and subsequently re-optimized to describe the in vivo data
(Saragapani et al., 2003). For D5, the values of tissue/blood PCswere
calculated by dividing the tissue/air PCs by the model estimated
in vivo blood/air PCs. This approach results in a slightly higher
blood/air coefﬁcient (0.5 for rat) while conserving the tissue/blood
relationship observed of the in vitro estimation.
2.2. Step 2: Coordinating models across species (rodent to human)
We next combined the rodent and human models into a single
model structure. We ﬁrst compared the rodent model structure
(from Step 1) to the existing D4 and D5 human inhalation PBPK
model structures (Reddy et al. 2003, 2008). The previous human
models describe the kinetic disposition of inhaled D4 and D5 in
humans with six compartments, incorporation of a MLP pool and
chemical speciﬁc deep tissue compartments. The original de-
scriptions used only one deep compartment to describe the liver
and the lung tissue concentrations and a single compartment to
describe fat concentrations. This lumping approach was a result of
the limited human tissue data (plasma, exhaled breath, and urine)from which the model could be developed (Tables Se1). The steps
in modifying the human models (Reddy et al. 2003, 2008) were
similar to those taken with the rodent models. These changes
include conversion of the plasma compartment to a blood
compartment, use of mass-based parameters to describe kinetics in
the deep tissue compartments, and saturable liver metabolism
(Table 1). The original D4 human inhalation model (Reddy et al.,
2003) did not have a lung compartment. The integrated model
has a deep lung compartment in order to describe D5 tissue time
courses but is toggled off for D4 simulations. The chemical speciﬁc
metabolite sub-model for humans was the same as that used in the
rodent model.2.2.1. Datasets
D4: Sixmale volunteers were exposed to 10 ppmvapor of 14C-D4
for 1 h while performing intermittent exercise (Utell et al., 1998).
Total radioactivity was determined for blood, exhaled breath, and
urine samples. Blood samples were collected during and after
exposure up to 24 h post-exposure. Exhaled breath samples were
collected up to 72 h after the cessation of the exposure. Urine
samples were collected up to 7 days post-exposure. Individual
silanol metabolites were measured in these urine samples.
D5: Three male and two female volunteers were exposed to D5
vapor at 10 ppm for 1 h (Plotzke et al., 2002). During the exposure,
subjects performed intermittent exercise, alternating rest and ex-
ercise periods on a regular interval. The corresponding changes in
the ventilation rate and the minute volume were recorded. Blood
and exhaled breath samples were collected during the exposure
and the post-exposure period up to 24 h after the cessation of the
exposure.2.2.2. Parameter estimation
The physiological values for tissue volumes and blood ﬂow rates
for humans were from the literature and presented in Table 2.
Model parameter values for D4 and D5 are listed in Tables 3 and 4
Partition coefﬁcients: Human blood: air PCs for D4 and D5 were
estimated by visual optimization of the model PCs to the individual
human data from the inhalation study. The human tissue: air PCs
for D4 and D5were the same as used in the current rat models. This
decision resulted in greater values for PC tissue: air for the liver and
slowly perfused compartments compared to the values used in the
earlier PBPK models. The tissue: blood PCs for the current human
model were calculated from the following ratios:
Tissue : blood ¼ rat PC tissue : air=model estimated PC blood
: air
Metabolism: Individual human MeM metabolic parameters for
D4 and D5 were estimated as done for the rat D5 metabolic pa-
rameters. D5 individual human blood and exhaled breath data and
D4 blood, exhaled breath and urine data were used to obtain esti-
mates for each of the individuals. Vmax was adjusted based on in-
dividual data while setting Km to a sufﬁciently high value to ensure
linear kinetics. After estimating values of these parameters for in-
dividual volunteers, these values were averaged to obtain a single
human value for simulating averaged population data.
Metabolite Sub-Model: The parameters for the D4 and D5
metabolite sub-model were adapted from the combined rat model
from Step 1.
Mobile Lipid Pool: MLP parameters for D4 and D5, Kmlp and Kre-
moval, were visually optimized using the individual blood and
exhaled breath concentrations. Parameters for individuals were
then averaged to obtain the corresponding population parameters.
Deep Compartments: Deep compartments and associated
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retained in the current structure (Fig. 1). The D5 model structure
has blood, lung and liver deep compartments. The Reddy et al.
(2003) model for D4 only included a deep fat compartment.
Simulation of the human D4 data sets with inclusion of a deep liver
compartment improved the model ﬁt to the data and therefore, the
deep liver compartment was retained in the uniﬁed D4 model.
The mass-transfer coefﬁcients for the slowly perfused and deep
compartments were initially optimized using individual blood and
exhaled breath data in individuals and then the averaged individual
parameter values for D5 were successfully used to simulate the
blood and exhaled breath data at the population level. Simulation
of the D4 time-course data at the population level, however,
required re-optimization of the ﬁnal populations level parameter
values.
2.3. Step 3: Combining routes of exposure (inhalation and dermal)
We next added the dermal route of exposure for humans using
the same dermal sub-model structure for D4 and D5 as was used in
Reddy et al. (2007) (Fig. 1e). Two processes regulate absorption of
cVMSs from the skin surface: absorption from the application site
to the skin tissue and evaporation of cVMSs from the skin surface at
the site of application. Upon absorption into the skin, cVMSs either
transfer into the venous blood for systemic distribution or are
retained in a deep skin compartment with transfer back to the skin
compartment for either absorption to blood or evaporation to air.
2.3.1. Datasets
13C-labeled D4 (Plotzke et al., 2000a, b) or D5 (Plotzke et al.,
2002) was applied to the axillae of three male and three female
subjects. A total of 1.4 g (males) or 1.0 g (females) was split equally
between both axillae. The material was allowed to absorb and
evaporate for 5 min. Blood and exhaled air samples were collected
over various time periods before and after the exposure.
2.3.2. Parameter estimation
We estimated skin-speciﬁc rate constants using the dermal-only
dataset with other model parameters identical to those used for
inhalation. The evaporation rates (Kevpc) for D4 (Table 3) and D5
(Table 4) were experimentally derived in vitro. The remaining skin
compartment parameters were based on visual optimization of the
model simulation to the dermal exposure data for blood and
exhaled breath concentrations.
2.4. Sensitivity analysis
We conducted a sensitivity analysis of the D4 and D5 model for
rat (inhalation) and human (inhalation and dermal). Sensitivity was
assessed in the rat using a single 6 h exposure to either D4 or D5 at
7 ppm while the human was evaluated using the human the
exposure scenarios presented in Figs. 5 and 6. The average blood
concentration over a 24 h timeframe (calculated as AUC/Time) for
each siloxane and exposure scenario was used to assess the
importance of speciﬁc parameters on the most likely dose metric
for cross-species extrapolation to evaluate points of departure.
Normalized sensitivity coefﬁcients (fractional change in output
divided by fractional change in input) were calculated with the
forward difference method. Changes in the average blood concen-
tration for either D4 or D5 were calculated for 1% changes of each
parameter. A parameter was deemed sensitive if the resulting co-
efﬁcient was >0.10 in absolute value. Only parameters meeting the
sensitivity cutoff for at least one endpoint are presented in the
results.3. Results
3.1. Model evaluation
We developed a single MC-MD route PBPK model for cVMSs
(Fig. 1) using a nested approach that built upon an original D5 ro-
dent model structure. The current rat model structure describes the
timeecourse concentrations of total radiolabeled and parent D4
and D5 in exhaled breath, blood, tissues and urine during and
following a both single (Fig. 2) and multiple (Fig. 3) exposure levels
at several concentrations using a consistent set of chemical and
species speciﬁc parameters (Tables 3 and 4). To ensure consistency
between this combined multi-compound, multi-dose model and
the original D4 and D5 models, the simulated time-averaged
plasma and liver concentrations in the rat following 160 ppm D5
and 700 ppm D4 were compared with the simulation results from
the original PBPK models (results not shown). Although no formal
statistics were applied for curve ﬁtting, this integrated, MC-MD
model did as well as the earlier model bespoke models in
describing the diverse data sets underpinning model development.
The richness of the time-course kinetic data with these silox-
anes and their unusual distributional characteristics - extremely
high blood clearance of free chemical and high fat: blood parti-
tioning - have provided a rare opportunity to better understand the
distribution of lipophilic compounds into body compartments.
With most moderately lipophilic compounds, lower clearance and
more modest fat: blood partitioning, obscure the kinetic processes
associated with loss of compounds from tissue after cessation of
inhalation. The observations of slower release than expected from
simple, one-compartment depictions of tissues with these silox-
anes is simply indicative of more physiologically-realistic disposi-
tion of lipophilic compounds into cells that are themselves
comprised of diverse intracellular compartments - endoplasmic
reticulum, mitochondria, nucleus/nucleolus, liposomes, and lyso-
zymes, etc. - all surrounded by lipid based membranes. Our multi-
compartment fat depots in tissues such as lung and liver likely
represent differential diffusional characteristics into and out of
these intracellular lipid pools. This same behavior should occur
with other compounds. Time course studies for kidney, liver, lung,
etc. with other moderately lipophilic volatiles, such as styrene,
could be mined to evaluate multi-compartment tissue structures
with a more diverse group of compounds.
cVMSs are extensively cleared from the body by exhalation of
free parent material (equivalent to total radioactivity in exhaled
breath; Fig. 2b, e; Fig. 3c, g) and hepatic metabolism leading to
various polar silanols (Varaprath et al., 1999, 2003). As became
apparent through the previous modeling efforts, measured plasma
concentrations of parent cVMSs represent both a bound, seques-
tered pool of siloxane and a free, circulating portion of the siloxane
that is available for distribution to other tissues and for exhalation
from the lung (Fig. 4c, d). In our MC-MD model, the unavailable
pool of material in the MLP compartment is presumed to be blood
lipids. Identiﬁcation of the MLP pool as the most likely carrier re-
mains a strong hypothesis that will beneﬁt from more detailed
analysis of siloxanes in various components of plasma.
Our MC-MD model has dose-dependent, saturable hepatic
metabolism and simulates the time-course concentrations of both
parent siloxane and total silanol metabolites separate from total
radiolabeled equivalents (Fig. 4a, b). For D5, the model equations
capture both circulating blood and tissue concentrations of the
hydroxylated D5 metabolite (data not shown). Urinary time-course
data for individual silanols metabolites were included in the ﬁrst
human PBPKmodel by Reddy et al. (2003) and compared to urinary
time course data from the volunteers. Further time course studies
of plasma and/or urinary concentrations of individual silanols
Fig. 2. Data (symbols) and model simulations (lines) of time-course concentrations of parent D4 in (A) plasma (B) rate of total amount of radiolabeled equivalents of D4 in exhaled
breath (equivalent to parent D4 for exhaled breath. Parent accounted for all radioactivity) and (C, F) rate of amount radiolabeled equivalents of D4 in urine following a single 6-h
inhalation exposure of male rats to 700, 70 or 7 ppm D4. (D) Plasma concentration (E) rate of total amount of radiolabeled equivalents of D5 in exhaled breath and (F) rate of amount
radiolabeled equivalents of D5 in urine following a single 6-hr inhalation exposure of male rats to 7 and 160 ppm D5.
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describe the kinetic behavior of individual silanol metabolites, such
as dimethylsilanediol (DMSD), across compounds and exposure
routes in rodents.
The next step in developing the MC-MD model structure built
on the rat model to describe the kinetic behavior of the cVMSs in
humans following inhalation exposure. The interspecies extension
to the MC-MD model adequately described both individual (datanot shown) and population time-course data of total D4 in exhaled
breath, plasma (Fig. 5a, b) and total D5 in exhaled breath and
plasma (Fig. 6a, b) following inhalation exposure. Compared to the
original human inhalation model code a deep lung, fat and liver
compartment were included in the human MC-MD model to
maintain consistency across species. Although the amount of D4 in
the deep liver compartment was very small in the MC-MD model
simulations, inclusion of this compartment improved the visual ﬁt
Fig. 3. Data (symbols) and model simulations (lines) of time-course concentrations of parent D4 in (A) plasma and (B) fat (C) rate of total amount of radiolabeled equivalents of D4
in exhaled breath and (D) rate of amount radiolabeled equivalents of D4 in urine following 15 days of inhalation exposure of male rats to 700, 70 or 7 ppm D4. (E) Plasma and (F) fat
concentrations (G) rate of total amount of radiolabeled equivalents of D5 in exhaled breath and (H) rate of amount radiolabeled equivalents of D5 in urine following 15 days of
inhalation exposure of male rats to 7 or 160 ppm D5.
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Fig. 4. Data (symbols) and model simulations (lines) of the time-course plasma concentrations of total radiolabeled equivalents (red), parent siloxane (blue) and calculated
concentrations of metabolites (green) in male rats following a single 6-h inhalation exposure to (A) 700 ppm D4 or (B) 160 ppm D5. Measured plasma concentrations of parent
siloxane shown in A and B (blue) represent the lipid bound material and the free, circulating material available for distribution to other tissues and exhalation from the lung for (C)
D4 or (D) D5.
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termination of exposure while having no effect on simulations of
the urine or blood data.
The dermal exposure route was added after ﬁnalizing the
inhalation model structure and its parameterization. Based on the
wealth of data available for dermal exposures from in vitro and
in vivo human skin studies and in vivo rodent studies, modeling of
the dermal uptake had three compartments - a skin surface depot, a
skin tissue compartment from which compound could transfer
back to the skin or move into either a deep tissue compartment or
to the venous blood and the deep tissue storage compartment of
the skin. The deep compartment likely represents siloxanes
retained in the stratum corneum that are then slowly released into
the viable epidermis and bloodstream upon termination of expo-
sure (Reddy et al., 2007). Upon termination of exposure, cVMSs in
the viable epidermis can either diffuse into blood or back to the skin
surface for evaporation. While this description was essential to
capture the time-course behavior of cVMSs following dermal
application, the speciﬁc depots in the skin during absorption and
the period of persistence in skin over the 24 h are not absolutely
well-deﬁned. The skin-speciﬁc uptake parameters were estimated
using the dermal-only dataset while keeping all other model pa-
rameters determined from the ﬁtting of the inhalation studies
constant at the population-level. We also note that the dermal
studies were with axilla skin that absorbs chemicals more rapidly
than other skin areas. Absorbed dose and circulating cVMS con-
centrations are expected to be lower for siloxane exposures to other
skin surfaces. Overall, the integrated MC-MD PBPK model forcVMSs simulated D4 and D5 time-course exhaled breath, blood and
various tissues data following the application of pure D4 (Fig. 5c, d)
or D5 (Fig. 6c, d) onto the axilla skin.
3.2. Sensitivity analysis
The normalized sensitivity coefﬁcients for sensitive parameters
in at least one of the scenarios are shown in Tables Se3. Similar
results were seen between the rat and human for both D4 and D4
regardless of exposure route. The most sensitive parameter across
species and dose routes on the average blood concentrationwas the
blood: air partition coefﬁcient which was experimentally deter-
mined. This was followed by parameters related to the disposition
of siloxane in within the lipid handling system which includes the
liver (KMLP) and fat (KREMOVAL) and metabolic rates which were
estimated to ﬁt either the time-course concentration of parent
chemical in liver and fat or the difference between parent and total
radioactivity in liver and plasma. The rate constants for deep
compartments (liver and blood) showed limited sensitivity and
only in the human inhalation scenarios. Physiological parameters
including BW, cardiac output, fraction of blood ﬂow to liver fat,
rapidly and slowly perfused tissues as well as the fraction of BW
represented by blood and liver were sensitive for average blood
concentration. For the dermal exposure scenario, additional pa-
rameters related directly to the uptake of siloxane including the
dermal surface are exposed (DERMAREA1 and 2) and the pene-
tration rate into stratum corneum (KSKINC) and from skin tissue to
skin blood (KSKNBLD).
Fig. 5. Model simulation (lines) and data (symbols) (mean ± SD; n ¼ 5) of D4 in (A) exhaled breath and (B) plasma in male volunteers during and following 10 ppm D5 vapor
exposure for 1-h or (C) exhaled breath and (D) plasma during and following a single application of 1.4 g 13C-D4 to skin axilla.
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The main purpose of developing this integrated MC-MD PBPK
model was to provide a single model construct for use in risk
assessment applications for either D4 or D5 and to be able to
compare the kinetic disposition between these cVMSs. The process
of developing an integrated, multi-compound, multi-route, multi-
species PBPK model for D4 and D5 uncovered important ques-
tions and challenges to consider when combining several
customized models into a single model suitable for risk assessment
purposes. Selection of the appropriate datasets to optimize the
model parameters from an extensive body of kinetic studies
(Table 1) was the most critical decision for this process. To achieve
this overall purpose, individual model parameter values were
optimized to the datasets that were the most informative of the
various underlying kinetic processes regulating those parameters.
In general, the preferred data sets were from rats because they had
more extensive time-course data and included detailed collection
of tissues at various times post-exposure.
Following the parameterization of the model with select data-
sets, we conducted a broad evaluation of the model structure and
parameters with all the available datasets to ensure that the model
reproduced the time-course concentrations of both parent and
total radiolabeled material in several biological matrices, including
blood, tissues and exhaled breath with a single set of chemical and
species speciﬁc parameters (see Results section). This approach is
consistent with the recommended evaluative process to determinethe level of conﬁdence in a PBPK model for use in risk assessment
(WHO, 2010). The WHO (2010) guidance indicates that models
should be evaluated on the basis of their biological plausibility,
their conformance with experimental data, and the reliability of
their predictions of dose metrics relevant to the intended risk
assessment. Table 5 provides a summary of the characteristics of
our cVMS PBPK model relevant to each of these criteria.
The integration of models under a single construct highlights
the distinct attributes each cVMS have that result in chemical
speciﬁc unique blood and tissue distribution. By developing a single
model that incorporates key components of previous models, while
also simulating the entire set of existing data equally well as did
older more limited scope models, we have reduced the challenges
risk assessors often face in attempting to select the most appro-
priate model for a risk assessment. This integrated model is sufﬁ-
ciently robust to derive relevant dose metrics, such as area under
the curve (AUC) or peak concentration of parent material in the
blood. The free concentration of parent material in the blood also
provides a reasonable surrogate for target tissue dose because
parent cVMSs partition fairly equally between blood and tissues,
with the exception of the fat tissue. These dose metrics can be used
to assess the best metric for understanding apical responses in test
animals. These same dose metrics, i.e., those estimated to be best
associated with outcomes in test animals, can be estimated for the
expected human exposures following individual or combined
dermal and inhalation exposures of workers, consumer or the
general population to D4 and D5. The dose measures also become
Fig. 6. Model simulation (lines) and data (symbols) (mean ± SD; n ¼ 3) of D5 in (a) exhaled breath and (b) plasma in male volunteers during and following 10 ppm D5 vapor
exposure for 1-h (c) exhaled breath and (d) plasma during and following a single application of 1.4 g 13C-D5 to skin axilla.
Table 5
Evaluation of model consistency with WHO (2010) PBPK modeling guidelines.
Key question (WHO, 2010) D4/D5 PBPK Model Level of
conﬁdence
Does the model structure and parameters have a reasonable
biological basis?
Model structure, code and parameters have appropriate biological bases and do not violate
any modeling principles or known boundary conditions for biological processes
High
How well does the PBPK model reproduce the chemical-speciﬁc
PK data under various experimental or exposure conditions?
The model reproduces the important features of multiple data sets using a consistent set of
species and chemical speciﬁc parameters for a variety of simulations:
 multiple dose levels
 oral, dermal and inhalation routes of exposures
 rodents and humans
High
How reliable is the PBPK model with regard to its predictions of
dose metrics relevant to risk assessment?
The model reliably reproduces the most plausible dose metric associated with hazard
endpoints used in risk assessments (parent cyclic siloxane AUC in blood) in both rats and
humans at relevant dose levels and relevant exposure routes for consumer protection
High
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extrapolations for risk assessment. In this journal issue, Gentry
et al. (2015) demonstrated the applicability of this integrated
model in a global “harmonized” risk assessment on D5 to meet
requirements for substance-speciﬁc risk assessments conducted by
regulatory agencies globally.
Having one common model also allowed us to examine if there
were outliers in the data or other kinetic processes that had not
been adequately described with this model. This global evaluation
of the datasets with a single model demonstrated that the kinetic
disposition of cVMS is very consistent across dose levels, species
and for both dermal and inhalation routes of exposure. Although
consumers are exposed to cVMSs primarily from the dermal and
inhalation routes, there is aminor contribution to total exposure viathe oral route. The kinetic dispositions of D4 and D5were evaluated
following high oral doses in various lipophilic vehicles or as neat
material (Plotzke, 1998). Modeling of these data indicated that the
uptake and distribution of the cVMSs following these high oral
exposures in rats differed substantially from the kinetic behavior
following dermal and inhalation exposures likely due to the form of
the cVMSs absorbed from the GI tract in lipophilic vehicles
(Saragapani et al., 2003). An oral study at more environmentally
relevant exposure levels using a vehicle more consistent with a
rodent food matrix was recently conducted to investigate dose and
vehicle dependent kinetics (Domoradzki et al., 2015) and evaluated
with a PBPK model (McMullin et al., 2015).
The concentrations of the cVMSs in the body are regulated by
the low blood: air partitioning and high hepatic clearance, leading
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blood for both dermal and inhalation exposure. Although it takes
days to weeks for D4 and D5 to reach steady state levels in the fat
due to the high blood: fat partitioning, these materials are not ex-
pected to bio accumulate in the blood or systemic tissues due to
rapid clearance by other processes (exhalation due to low blood: air
partitioning and high hepatic clearance due to high afﬁnity meta-
bolism in liver) that remove the material from the circulation. As
such, rats repeatedly exposed to D4 or D5 via inhalation rapidly
reach stable periodicity for plasma concentrations. Andersen et al.
(2008) used a generic PBPK model to assess attributes that inﬂu-
ence tissue concentrations of lipophilic volatile compounds and
demonstrated that highly metabolized, lipophilic compounds with
low blood: air partitioning, such as D5, do not accumulate in blood
or systemic tissues with repeat exposures. Their conclusion was
further supported by an absence of an increase in D5-tissue con-
centrations after a 6-month inhalation exposure during the
conduct of a chronic bioassay (Jean et al., 2015; in this issue).
This integrated MC-MD model can also be used to describe the
cross-species relationships between other relevant dose metrics
associated with point of departures (PoDs) derived from the animal
studies. These PoDs could include either parent chemical or
metabolite based metrics, such as total silanols, in plasma or tissue.
Importantly, there are characteristics of the rat kinetics, speciﬁcally
inducible metabolism at higher D4 exposures that are not relevant
for human exposures at levels much lower than those in the rat
studies. Although limited biomonitoring data currently exist on the
cVMS materials (Xu et al., 2012, 2015), a single model for the cVMS
materials will have also applications for interpreting biomonitoring
data in a risk/exposure context.
On a ﬁnal note, we foresee two other contributions expected to
arise from developing our integrated model. First, as data sets
accumulate for other lowmolecular weight siloxanes, the observed
kinetic behavior of these materials can be more easily compared
with that seen for D4 and D5 to assess similarities or differences in
the processes accounting for uptake, distribution and elimination
of a wider variety of low molecular weight siloxanes. Secondly,
metabolism of cVMSs and of longer chain linear siloxanes produce
common silanol metabolites. With a limited suite of pharmacoki-
netic time course studies on speciﬁc silanols, this model could be
expanded to predict these various silanols in diverse populations
for any number of siloxanes.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.yrtph.2015.12.010.
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